-
1تقرير
المصدر: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05511844Test
-
2تقرير
المؤلفون: Jiangsu HengRui Medicine Co., Ltd.
المصدر: An Open-label, Phase 2 Study of Pyrotinib Maleate in Advanced Solid Tumors Patients With HER2( Erb-B2 Receptor Tyrosine Kinase 2)-Postive
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04179656Test